10-Q 1 form10-q.htm
false Q3 --03-31 2024 0001630113 P1Y 0001630113 2023-04-01 2023-12-31 0001630113 2024-02-20 0001630113 2023-12-31 0001630113 2023-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2023-12-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2023-03-31 0001630113 BTCY:PreferredStockOneMember 2023-12-31 0001630113 BTCY:PreferredStockOneMember 2023-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001630113 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001630113 2023-10-01 2023-12-31 0001630113 2022-10-01 2022-12-31 0001630113 2022-04-01 2022-12-31 0001630113 us-gaap:PreferredStockMember 2023-09-30 0001630113 us-gaap:CommonStockMember 2023-09-30 0001630113 BTCY:SharesToBeIssuedMember 2023-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001630113 us-gaap:RetainedEarningsMember 2023-09-30 0001630113 2023-09-30 0001630113 us-gaap:PreferredStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001630113 BTCY:SharesToBeIssuedMember 2023-10-01 2023-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-31 0001630113 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001630113 us-gaap:PreferredStockMember 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-12-31 0001630113 BTCY:SharesToBeIssuedMember 2023-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001630113 us-gaap:RetainedEarningsMember 2023-12-31 0001630113 us-gaap:PreferredStockMember 2023-03-31 0001630113 us-gaap:CommonStockMember 2023-03-31 0001630113 BTCY:SharesToBeIssuedMember 2023-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001630113 us-gaap:RetainedEarningsMember 2023-03-31 0001630113 us-gaap:PreferredStockMember 2023-04-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-04-01 2023-12-31 0001630113 BTCY:SharesToBeIssuedMember 2023-04-01 2023-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-12-31 0001630113 us-gaap:RetainedEarningsMember 2023-04-01 2023-12-31 0001630113 us-gaap:PreferredStockMember 2022-09-30 0001630113 us-gaap:CommonStockMember 2022-09-30 0001630113 BTCY:SharesToBeIssuedMember 2022-09-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001630113 us-gaap:RetainedEarningsMember 2022-09-30 0001630113 2022-09-30 0001630113 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001630113 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001630113 BTCY:SharesToBeIssuedMember 2022-10-01 2022-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001630113 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001630113 us-gaap:PreferredStockMember 2022-12-31 0001630113 us-gaap:CommonStockMember 2022-12-31 0001630113 BTCY:SharesToBeIssuedMember 2022-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001630113 us-gaap:RetainedEarningsMember 2022-12-31 0001630113 2022-12-31 0001630113 us-gaap:PreferredStockMember 2022-03-31 0001630113 us-gaap:CommonStockMember 2022-03-31 0001630113 BTCY:SharesToBeIssuedMember 2022-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001630113 us-gaap:RetainedEarningsMember 2022-03-31 0001630113 2022-03-31 0001630113 us-gaap:PreferredStockMember 2022-04-01 2022-12-31 0001630113 us-gaap:CommonStockMember 2022-04-01 2022-12-31 0001630113 BTCY:SharesToBeIssuedMember 2022-04-01 2022-12-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-12-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-12-31 0001630113 us-gaap:RetainedEarningsMember 2022-04-01 2022-12-31 0001630113 2023-06-29 2023-06-29 0001630113 us-gaap:CommonStockMember 2023-06-19 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-04-01 2022-03-31 0001630113 2021-04-01 2022-03-31 0001630113 2020-04-01 2021-03-31 0001630113 2022-04-01 2023-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-12-31 0001630113 BTCY:TechnologyFeesMember 2023-10-01 2023-12-31 0001630113 BTCY:TechnologyFeesMember 2022-10-01 2022-12-31 0001630113 BTCY:TechnologyFeesMember 2023-04-01 2023-12-31 0001630113 BTCY:TechnologyFeesMember 2022-04-01 2022-12-31 0001630113 BTCY:DeviceSalesMember 2023-10-01 2023-12-31 0001630113 BTCY:DeviceSalesMember 2022-10-01 2022-12-31 0001630113 BTCY:DeviceSalesMember 2023-04-01 2023-12-31 0001630113 BTCY:DeviceSalesMember 2022-04-01 2022-12-31 0001630113 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001630113 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001630113 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001630113 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001630113 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001630113 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001630113 us-gaap:OfficeEquipmentMember 2023-12-31 0001630113 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001630113 BTCY:TwoSeriesANotesMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember 2021-03-31 0001630113 BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesMember 2022-03-31 0001630113 BTCY:SeriesANoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 0001630113 BTCY:SeriesANoteMember 2023-12-31 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-04-01 2023-12-31 0001630113 BTCY:SeriesBNotesMember BTCY:AccreditedInvestorsMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantOneMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantTwoMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2022-03-31 0001630113 BTCY:SeriesBNoteMember 2023-12-31 0001630113 BTCY:SeriesBNoteMember 2023-10-01 2023-12-31 0001630113 BTCY:SeriesBNoteMember 2023-04-01 2023-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2023-06-30 0001630113 BTCY:SeriesCNotesMember BTCY:AccreditedInvestorsMember 2023-03-31 0001630113 BTCY:SeriesCNotesMember 2023-07-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember 2023-09-30 0001630113 BTCY:SeriesCNotesMember BTCY:AccreditedInvestorsMember 2023-12-31 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember us-gaap:WarrantMember 2023-04-01 2023-12-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesCNotesMember 2023-04-01 2023-12-31 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember BTCY:SeriesCNotesMember 2023-04-01 2023-09-30 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2023-12-31 0001630113 BTCY:SeriesCNotesMember BTCY:NoteHoldersMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember BTCY:PlacementAgentsWarrantsMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2023-10-01 2023-12-31 0001630113 BTCY:SeriesCNotesMember 2023-12-31 0001630113 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-09-25 0001630113 2023-10-25 2023-10-25 0001630113 us-gaap:PreferredStockMember 2023-09-25 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 2023-01-23 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-10-01 2023-12-31 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember 2023-04-01 2023-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember BTCY:FirstFourWeeksMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-10-01 2023-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-04-01 2023-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-01 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-04-01 2023-12-31 0001630113 BTCY:SeriesAConvertibleNoteHoldersMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2023-12-31 0001630113 BTCY:NewPromissoryNoteMember 2023-10-01 2023-12-31 0001630113 BTCY:NewPromissoryNoteMember 2023-04-01 2023-12-31 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember BTCY:FirstFourWeeksMember 2023-03-29 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember BTCY:RemainingThirtySixWeeksMember 2023-03-29 2023-03-29 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 2023-07-18 0001630113 BTCY:SeriesANotesMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-12-31 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-10-01 2023-12-30 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-04-01 2023-12-31 0001630113 2023-06-01 2023-06-30 0001630113 2023-06-30 0001630113 2023-12-01 2023-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 2023-07-13 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-10-01 2023-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-04-01 2023-12-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember BTCY:OneInvestorMember 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-12-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-10-01 2023-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-12-08 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-12-08 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-10-01 2023-12-31 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-04-01 2023-12-31 0001630113 BTCY:PromissoryNoteMember 2023-10-01 2023-12-31 0001630113 BTCY:PromissoryNoteMember 2023-04-01 2023-12-31 0001630113 2021-12-21 0001630113 2021-12-19 2021-12-21 0001630113 us-gaap:CashMember 2021-12-21 0001630113 BTCY:TermLoanMember 2023-10-01 2023-12-31 0001630113 BTCY:TermLoanMember 2022-10-01 2022-12-31 0001630113 BTCY:TermLoanMember 2023-04-01 2023-12-31 0001630113 BTCY:TermLoanMember 2022-04-01 2022-12-31 0001630113 2022-11-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-01 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-05-01 2021-05-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-10-01 2023-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2022-10-01 2022-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-04-01 2023-12-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2022-04-01 2022-12-31 0001630113 us-gaap:ConvertibleDebtMember 2023-04-01 2023-12-31 0001630113 us-gaap:ConvertibleDebtMember 2023-03-31 0001630113 us-gaap:ConvertibleDebtMember 2022-03-31 0001630113 us-gaap:ConvertibleDebtMember 2022-04-01 2022-12-31 0001630113 us-gaap:ConvertibleDebtMember 2023-12-31 0001630113 us-gaap:ConvertibleDebtMember 2022-12-31 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-12-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MinimumMember 2023-12-31 0001630113 srt:MaximumMember 2023-12-31 0001630113 srt:MinimumMember 2022-12-31 0001630113 srt:MaximumMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2023-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2022-04-01 2022-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2023-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2023-12-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2022-12-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2022-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2023-12-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2023-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-18 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 BTCY:PurchaseAgreementMember BTCY:BeneficiaryMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember BTCY:BeneficiaryMember 2023-09-19 0001630113 BTCY:PurchaseAgreementMember 2023-04-01 2023-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-12-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-04-01 2022-06-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-04-01 2022-12-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-06-30 0001630113 BTCY:IssuanceOfCommonSharesMember 2022-04-01 2022-06-30 0001630113 us-gaap:WarrantMember 2022-04-01 2022-06-30 0001630113 BTCY:IssuanceOfCommonSharesMember srt:MinimumMember 2022-04-01 2022-06-30 0001630113 2022-04-01 2022-06-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-07-01 2022-09-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-09-30 0001630113 2022-07-01 2022-09-30 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-10-01 2022-12-31 0001630113 BTCY:ConvertiblePromissoryNotesMember 2022-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2022-10-01 2022-12-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2023-10-01 2023-12-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2023-12-31 0001630113 BTCY:NoteHolderMember 2023-12-31 0001630113 BTCY:PlacementAgentWarrantsMember 2023-12-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-04-01 2022-06-30 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-06-30 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-09-30 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-10-01 2022-12-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-10-01 2023-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2022-10-01 2022-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-04-01 2023-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2022-04-01 2022-12-31 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember 2023-03-31 0001630113 BTCY:BrokerWarrantsMember 2023-03-31 0001630113 BTCY:ConsultantWarrantsMember 2023-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2023-03-31 0001630113 BTCY:BrokerWarrantsMember 2023-04-01 2023-12-31 0001630113 BTCY:ConsultantWarrantsMember 2023-04-01 2023-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2023-04-01 2023-12-31 0001630113 BTCY:BrokerWarrantsMember 2023-12-31 0001630113 BTCY:ConsultantWarrantsMember 2023-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2023-12-31 0001630113 BTCY:BrokerWarrantsMember srt:MinimumMember 2023-12-31 0001630113 BTCY:BrokerWarrantsMember srt:MaximumMember 2023-12-31 0001630113 BTCY:ConsultantWarrantsMember srt:MinimumMember 2023-12-31 0001630113 BTCY:ConsultantWarrantsMember srt:MaximumMember 2023-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember srt:MinimumMember 2023-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember srt:MaximumMember 2023-12-31 0001630113 us-gaap:StockOptionMember 2023-03-31 0001630113 us-gaap:StockOptionMember 2023-04-01 2023-12-31 0001630113 us-gaap:StockOptionMember 2023-12-31 0001630113 BTCY:NewLeaseAgreementMember 2021-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-01 2023-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-10-01 2022-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-12-31 0001630113 us-gaap:OfficeEquipmentMember 2023-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001630113 us-gaap:OfficeEquipmentMember 2023-04-01 2023-12-31 0001630113 us-gaap:LeaseholdImprovementsMember 2023-04-01 2023-12-31 0001630113 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2024-01-31 0001630113 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-01-31 0001630113 us-gaap:SubsequentEventMember BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-02-29 0001630113 us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001630113 us-gaap:SubsequentEventMember 2024-02-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the quarterly period ended December 31, 2023
     
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the period from ______________ to_______________

 

Commission file number: 001-40761

 

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

 

Nevada   30-0983531
State or other jurisdiction of
incorporation or organization)
 

(I.R.S. Employer

Identification No.)

 

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065

(Address of principal executive offices)

 

(800) 590 4155

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act).

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BTCY   The NASDAQ Stock Market LLC

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 9,258,957 shares of Common Stock, $0.001 par value, at February 20, 2024. As at that same date, the Company also has 160,672 Exchangeable Shares outstanding that convert directly into common shares, which when combined with its Common Stock produce an amount equivalent to 9,419,629 outstanding voting securities.

 

 

 

 
 

 

BIOTRICITY INC.

 

Part I – Financial Information  
   
Item 1 – Condensed Consolidated Financial Statements 3
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations 36
Item 3 – Quantitative and Qualitative Disclosures About Market Risk 48
Item 4 – Controls and Procedures 48
   
Part II – Other Information 49
   
Item 1 – Legal Proceedings 49
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 49
Item 3 – Defaults Upon Senior Securities 49
Item 4 – Mine Safety Disclosures 49
Item 5 – Other Information 49
Item 6 – Exhibits 49
Signatures 50

 

 2 

 

 

PART 1

FINANCIAL INFORMATION

 

Item 1 – Condensed Consolidated Financial Statements

 

Condensed Consolidated Balance Sheets as of December 31, 2023 (unaudited) and March 31, 2023 (audited) 4
   
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended December 31, 2023 and 2022 (unaudited) 5
   
Condensed Consolidated Statements of Stockholders’ Deficiency for the three and nine months ended December 31, 2023 and 2022 (unaudited) 6
   
Condensed Consolidated Statements of Cash Flows for the nine months ended December 31, 2023 and 2022 (unaudited) 10
   
Notes to the Condensed Consolidated Financial Statements 11

 

 3 

 

 

BIOTRICITY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2023 (unaudited) AND MARCH 31, 2023 (audited)

(Expressed in US Dollars)

 

   As of
December 31,
2023
   As of
March 31,
2023
 
   $   $ 
CURRENT ASSETS          
Cash   85,094    570,460 
Accounts receivable, net   1,573,583    1,224,137 
Inventories [Note 3]   2,048,910    2,337,006 
Deposits and other receivables   224,895    588,599 
Total current assets   3,932,482    4,720,202 
           
Deposits [Note 10]   85,000    85,000 
Long-term accounts receivable   135,560    96,344 
Property and equipment [Note 12]   17,041    21,506 
Operating right of use assets [Note 10]   1,316,135    1,587,492 
TOTAL ASSETS   5,486,218    6,510,544 
           
CURRENT LIABILITIES          
Accounts payable and accrued liabilities [Note 4]   7,558,745    5,042,476 
Convertible promissory notes and short term loans [Note 5]   7,922,097    4,774,468 
Term loan, current [Note 6]   1,800,000     
Derivative liabilities [Note 8]   928,333    1,008,216 
Operating lease obligations, current [Note 10]   409,702    335,608 
Total current liabilities   18,618,877    11,160,768 
           
Federally guaranteed loans [Note 7]   870,800    870,800 
Term loan [Note 6]   10,533,425    12,178,809 
Derivative liabilities [Note 8]   1,139,293    759,065 
Operating lease obligations [Note 10]   1,051,321    1,386,487 
TOTAL LIABILITIES   32,213,716    26,355,929 
           
Mezzanine Equity          
Series B Convertible Redeemable preferred stock, $0.001 par value, 600 and no shares authorized as of December 31, 2023 and March 31, 2023, respectively, 220 and no shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively [Note 9]   1,028,856    - 
           
STOCKHOLDERS’ DEFICIENCY          
Preferred stock, $0.001 par value, 9,979,400 and 9,980,000 shares authorized as of December 31, 2023 and March 31, 2023, respectively, 1 share issued and outstanding as of December 31, 2023 and March 31, 2023 [Note 9]   1    1 
Series A preferred stock, $0.001 par value, 20,000 shares authorized as of December 31, 2023 and March 31, 2023, 6,304 shares issued and outstanding as of December 31, 2023 and March 31, 2023 [Note 9]   6    6 
Common stock, $0.001 par value, 125,000,000 shares authorized as of December 31, 2023 and March 31, 2023. Issued and outstanding common shares: 9,258,957 and 8,508,052 as of December 31, 2023 and March 31, 2023, respectively, and exchangeable shares of 160,672 and 244,458 outstanding as at December 31, 2023 and March 31, 2023, respectively [Note 9]   9,420    8,753 
Shares to be issued, 3,955 shares of common stock as of December 31, 2023 and March 31, 2023 [Note 9]   24,999    24,999 
Additional paid-in-capital   95,560,789    92,844,478 
Accumulated other comprehensive income/(loss)   (251,888)   (152,797)
Accumulated deficit   (123,099,681)   (112,570,825)
TOTAL STOCKHOLDERS’ DEFICIENCY   (27,756,354)   (19,845,385)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY   5,486,218    6,510,544 

 

Commitments and contingencies [Note 11]

 

Subsequent Events [Note 14]

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

 4 

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (unaudited)

(Expressed in US Dollars)

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
    $    $    $    $ 
                     
REVENUE   2,972,972    2,459,181    8,885,034    6,896,622 
                     
Cost of Revenue   804,986    1,057,215    2,801,066    2,989,290 
NET REVENUE   2,167,986    1,401,966    6,083,968    3,907,332 
                     
EXPENSES                    
Selling. general and administrative expenses   2,996,804    4,363,964    10,004,350    13,336,888 
Research and development expenses   452,956    876,460    1,863,551    2,526,550 
TOTAL OPERATING EXPENSES   3,449,760    5,240,424    11,867,901    15,863,438 
LOSS FROM OPERATIONS   (1,281,774)   (3,838,458)   (5,783,933)   (11,956,106)
                     
Interest expense [Note 5, 6 and 9]   (790,080)   (413,402)   (2,203,860)   (1,205,342)
Accretion and amortization expenses [Note 5,6]   (422,706)   (51,061)   (1,576,345)   (151,970)
Change in fair value of derivative liabilities [Note 8]   (326,683)   (99,705)   (244,014)   (469,971)
Gain (loss) upon convertible promissory notes conversion and redemption   2,148    5,391    15,280    (85,537)
Other (expense) income [Note 13]   11,004    (119,880)   (118,941)   (116,989)
NET LOSS BEFORE INCOME TAXES   (2,808,091)   (4,517,115)   (9,911,813)   (13,985,915)
Income taxes                
NET LOSS BEFORE DIVIDENDS   (2,808,091)   (4,517,115)   (9,911,813)   (13,985,915)
                     
Adjustment: Preferred Stock Dividends   (237,904)   (230,374)   (617,043)   (690,330)
NET LOSS ATTRIBUTABLE TO COMMON STOCKLHOLDERS   (3,045,995)   (4,747,489)   (10,528,856)   (14,676,245)
                     
Translation adjustment   (204,501)   (72,823)   (99,091)   625,698 
                     
COMPREHENSIVE LOSS   (3,250,496)   (4,820,312)   (10,627,947)   (14,050,547)
                     
LOSS PER SHARE, BASIC AND DILUTED   (0.339)   (0.546)   (1.191)   (1.699)
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING   8,979,430    8,690,506    8,842,890    8,635,900 

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

 5 

 

 

BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (unaudited)

 

                                         
   Preferred stock   Common stock and exchangeable common shares   Shares to be
Issued
  

 

Additional paid in capital

   Accumulated other comprehensive income/(loss)   Accumulated deficit   Total 
  

Shares

   $   Shares   $   Shares   $  

$

   $   $   $ 
Balance, September 30, 2023 (unaudited)   6,305    7    8,810,253    8,811    3,955    24,999    93,338,220    (47,387)   (120,053,686)   (26,729,036)
Issuance of warrants for private placement holders [Note 9]                                 1,524,719              1,524,719 
Issuance of warrants for brokers [Note 9]                                 127,853              127,853 
Conversion of preferred shares into common shares [Note 9]           562,251    562            353,957            354,519 
Issuance of shares for services [Note 9]           47,125    47            45,900            45,947 
Stock based compensation - ESOP [Note 9]                           170,140            170,140 
Translation adjustment                               (204,501)       (204,501)
Net loss before dividends for the period                                           (2,808,091)   (2,808,091)
Preferred stock dividends                                   (237,904)   (237,904)
Balance, December 31, 2023 (unaudited)   6,305    7    9,419,629    9,420    3,955    24,999    95,560,789    (251,888)   (123,099,681)   (27,756,354)

 

 6 

 

 

   Preferred stock   Common stock and exchangeable common shares   Shares to be
Issued
   Additional paid in capital   Accumulated other comprehensive income/(loss)   Accumulated deficit   Total 
   Shares   $   Shares   $   Shares   $   $   $   $   $ 
Balance, March 31, 2023 (audited)   6,305    7    8,752,510    8,753    3,955    24,999    92,844,478    (152,797)   (112,570,825)   (19,845,385)
Issuance of common stock           57,743    58            119,227            119,285 
Issuance of warrants for private placement holders [Note 9]                                 1,524,719              1,524,719 
Issuance of warrants for brokers [Note 9]                                 127,853              

127,853

 
Conversion of preferred shares into common shares [Note 9]           562,251    562            353,957            354,519 
Issuance of shares for services [Note 9]           47,125    47            45,900            45,947 
Stock based compensation - ESOP [Note 9]                           544,655            544,655 
Translation adjustment                               (99,091)       (99,091)
Net loss before dividends for the period                                   (9,911,813)   (9,911,813)
Preferred stock dividends                                   (617,043)   (617,043)
Balance, December 31, 2023 (unaudited)   6,305    7    9,419,629    9,420    3,955    24,999    95,560,789    (251,888)   (123,099,681)   (27,756,354)

 

 7 

 

 

   Preferred stock   Common stock and exchangeable common shares   Shares to be
Issued
   Additional paid in capital   Accumulated other comprehensive (loss) income   Accumulated deficit   Total 
   Shares   $   Shares   $   Shares   $   $   $   $   $ 
Balance, September 30, 2022 (unaudited)   6,802    8    8,649,721    8,650    3,955    24,999    92,378,740    (70,135)   (102,965,898)   (10,623,636)
Conversion of convertible notes into common shares [Note 9]           39,830    40            211,562            211,602 
Preferred stock purchased back via cash [Note 8]   (497)   (1)                   (431,128)           (431,129)
Issuance of shares for services [Note 9]           17,544    17            112,614            112,631 
Issuance of warrants for services [Note 9]                           77,780            77,780 
Exchange of warrants for promissory notes                           (71,768)           (71,768)
Stock based compensation - ESOP [Note 9]                           63,125            63,125 
Translation adjustment                               (72,823)       (72,823)
Net loss before dividends for the period                                   (4,517,115)   (4,517,115)
Preferred stock dividends                                   (230,374)   (230,374)
Balance, December 31, 2022 (unaudited)   6,305    7    8,707,095    8,707    3,955    24,999    92,340,925    (142,958)   (107,713,387)   (15,481,707)

 

 8 

 

 

   Preferred stock  

Common stock and

exchangeable

common shares

   Shares to be
Issued
  

Additional

paid in

capital

  

Accumulated

other

comprehensive

(loss) income

  

Accumulated

deficit

   Total 
   Shares   $   Shares   $   Shares   $   $   $   $   $ 
Balance, March 31, 2022 (audited)   7,201    8    8,546,261    8,546    20,638    102,299    91,550,209    (768,656)   (93,037,142)   (2,144,736)
                                                   
Conversion of convertible notes into common shares [Note 9]           126,833    127            843,795            843,922 
Preferred stock purchased back via cash   (896)   (1)   -    -    -    -    (777,174)   -    -    (777,175)
Issuance of shares for services [Note 9]   -    -    22,035    22    -    -    150,396    -    -    150,418 
Exercise of warrants for cash [Note 9]   -    -    11,966    12    (16,683)   (77,300)   47,288    -    -    (30,000)
Issuance of warrants for services [Note 9]   -    -    -    -    -    -    232,526    -    -    232,526 
Exchange of warrants for promissory notes   -    -    -    -    -    -    (71,768)   -    -    (71,768)
Stock based compensation - ESOP [Note 9]   -    -    -    -    -    -    365,653    -    -    365,653 
Translation adjustment   -    -    -    -    -    -    -    625,698    -    625,698 
Net loss before dividends for the period   -    -    -    -    -    -    -    -    (13,985,915)   (13,985,915)
Preferred stock dividends   -    -    -    -    -    -    -    -    (690,330)   (690,330)
Balance, December 31, 2022 (unaudited)   6,305    7    8,707,095    8,707    3,955    24,999    92,340,925    (142,958)   (107,713,387)   (15,481,707)

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

 9 

 

 

BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED)

(Expressed in US Dollars)

 

           
   Nine Months Ended December 31, 
   2023   2022 
    $    $ 
           
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss   (9,911,813)   (13,985,915)
Adjustments to reconcile net loss to net cash used in operations:          
Stock based compensation   544,655    365,653 
Issuance of shares for services   45,947    150,418 
Issuance of warrants for services       232,526 
Accretion and amortization expenses   1,576,345    151,970 
Change in fair value of derivative liabilities   244,014    469,971 
(Gain) loss upon convertible promissory notes conversion   (15,280)   85,537 
Other expense regarding loss on debt modification   59,161    126,158 
Non-cash lease expense   271,357     
Property and equipment depreciation   4,465    4,465 
           
Changes in operating assets and liabilities:          
Accounts receivable, net   (377,579)   (40,799)
Inventories   288,096    (1,088,970)
Deposits and other receivables   363,704    (71,877)
Accounts payable and accrued liabilities   1,378,808    1,931,196 
Net cash used in operating activities   (5,528,120)   (11,669,667)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Redemption of preferred shares       (895,556)
Issuance of common shares, net of issuance costs   119,285     
Issuance of preferred shares, net of issuance costs   1,900,000    
Exercise of warrants for cash       12,500 
Proceeds from (repayments of) convertible notes, net   2,207,579    (61,238)
Proceeds from short term loan and promissory notes, net   744,333    1,889,144 
Preferred Stock Dividend   (18,016)   (940,731)
Net cash provided by financing activities   4,953,181    4,119 
           
Net change in cash during the period   (574,939)   (11,665,548)
Effect of foreign currency translation   89,573    50,040
Cash, beginning of period   570,460    12,066,929 
Cash, end of period   85,094    451,421 
           
Supplemental disclosure of cash flow information:          
Interest paid   1,638,991    771,273 
Taxes        

 

See accompanying notes to unaudited condensed consolidated interim financial statements

 

 10 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

1. NATURE OF OPERATIONS

 

Biotricity Inc. (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014, under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.

 

Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.

 

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements and should be read in conjunction with Biotricity’s audited consolidated financial statements for the years ended March 31, 2023 and 2022 and their accompanying notes.

 

The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the interim periods presented herein are not necessarily indicative of the results that may be expected for the year ending March 31, 2024. The Company’s fiscal year-end is March 31.

 

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated.

 

Reclassifications

 

Certain amounts presented in the prior year period have been reclassified to conform to current period condensed consolidated financial statement presentation. Interest expense related to debt principal, previously recorded as a selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss in the prior year, was reclassified as a non-operating expense.

 

Reverse Stock Split

 

On June 29, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to effect a one-for-six (1-for-6) share consolidation (the “Reverse Split”). The Reverse Split became effective on July 3, 2023. As a result of the Reverse Split, every six shares of the Company’s issued and outstanding common stock were automatically converted into one share of common stock, without any change in the par value per share or to the number of shares authorized and began trading on a post-Reverse Split basis under the Company’s existing trading symbol, “BTCY,” when the market opened on July 3, 2023. No fractional shares were outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock was automatically entitled to receive an additional fraction of a share of common stock to round up to the next whole share: 20,846 shares were issued for this purpose on July 19, 2023. The Reverse Split does not impact the amount of authorized common stock or par value per share. Lastly, the Reverse Split does not impact the amount of authorized, issued or outstanding shares of preferred stock.

 

All issued and outstanding common stock, common stock per share amounts and corresponding balance sheet accounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise and conversion price and the number of shares issuable upon the exercise or conversion of all outstanding stock options, warrants, convertible debt and equity instruments to purchase shares of common stock.

 

 11 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Going Concern, Liquidity and Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of December 31, 2023, had an accumulated deficit of $123.1 million and a working capital deficiency of $14.69 million. Those conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance of these condensed consolidated financial statements. The condensed consolidated financial statements do not include adjustments that might result from the outcome of this uncertainty.

 

Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. During fiscal year ended March 31, 2022, the Company raised $499,900 through government EIDL loan. The Company also raised total net proceeds of $14,545,805 through the underwritten public offering that was concurrent with its listing onto the Nasdaq Capital Markets. The Company raised additional net proceeds of $11,756,563 through a term loan transaction (Note 6) and made repayment of the previously issued promissory notes and short-term loans. In connection with this loan, the Company and Lender entered into a Guarantee and Collateral Agreement, as well as an Intellectual Property Security Agreement, wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets, as well as secured by the Company’s right title and interest in the Company’s Intellectual Property. During the fiscal year ended March 31, 2023, the Company raised short-term loans and promissory notes, net of repayments of $1,476,121 from various lenders, and also raised convertible notes, net of redemptions of $2,355,318 from various lenders. During the nine months ended December 31, 2023, the Company entered into a Series B preferred stock financing that generated $1.9 million in net proceeds and the Company raised additional convertible notes, net of redemptions of $2.2 million from various lenders. The Company also raised additional short-term loans and promissory notes, net of repayments, of $0.7 million from various lenders.

 

As we proceed with the commercialization of the Bioflux, Biotres, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures.

 

Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China and spread globally, causing significant disruption to the global and US economy. On March 20, 2020, the Company announced the precautionary measures taken as well as announcing the business impact related to the coronavirus (COVID-19) pandemic. Though its operations have since returned to a normal state, the extent to which the COVID-19 pandemic may continue to affect the economy and the Company’s operations may depend on future developments.

 

 12 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied.

 

Both the Bioflux cardiac outpatient monitoring device, and the Biotres device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred, or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.

 

The Company may also, from time to time, earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business.

 

The Company recognized the following forms of revenue for the three and nine months ended December 31, 2023 and 2022:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
   $   $   $   $ 
Technology fee sales   2,780,094    2,253,187    8,280,473    6,240,042 
Device sales   192,878    205,994    604,561    656,580 
Total   2,972,972    2,459,181    8,885,034    6,896,622 

 

 13 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Inventories

 

Inventory is stated at the lower of cost and market value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.

 

  

As of

December 31,

2023

  

As of

March 31,

2023

 
   $   $ 
Raw material   1,175,790    1,186,735 
Finished goods   873,120    1,150,271 
Inventories   2,048,910    2,337,006 

 

Significant accounting estimates and assumptions

 

The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

 

Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities.

 

Fair value of stock options

 

The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.

 

Fair value of warrants

 

In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.

 

 14 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Fair value of derivative liabilities

 

In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.

 

Functional currency  

 

Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.

 

Useful life of property and equipment  

 

The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.

 

Provisions  

 

Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, considering the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.

 

Contingencies  

 

Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.

 

Inventory obsolescence  

 

Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.

 

Incremental borrowing rate for lease  

 

The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.

 

 15 

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Earnings (Loss) Per Share

 

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings are computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was applied during the periods presented when conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.

 

Cash

 

Cash includes cash on hand and balances with banks.

 

Foreign Currency Translation

 

The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar, and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

 

Accounts Receivable

 

Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

 

 16 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Fair Value of Financial Instruments

 

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

 

● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

 

● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

 

● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally-guaranteed loans, term loans, accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

 

The fair value of financial instruments measured on a recurring basis is as follows:

 

   As of December 31, 2023 
Description  Total   Level 1   Level 2   Level 3 
Liabilities:                    
Derivative liabilities, short-term  $928,333   $   $   $928,333 
Derivative liabilities, long-term   1,139,293            1,139,293 
Total liabilities at fair value  $2,067,626   $   $   $2,067,626 

 

   As of March 31, 2023 
Description  Total   Level 1   Level 2   Level 3 
Liabilities:                    
Derivative liabilities, short-term  $1,008,216   $   $   $1,008,216 
Derivative liabilities, long-term   759,065            759,065 
Total liabilities at fair value  $1,767,281   $   $   $1,767,281 

 

There were no transfers between fair value hierarchy levels during the three and nine months ended December 31, 2023 and 2022.

 

 17 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follow:

 

Office equipment 5 years
Leasehold improvement 5 years

 

Impairment for Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at December 31, 2023 and March 31, 2023, the Company believes there was no impairment of its long-lived assets.

 

Leases

 

The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease liabilities, current, and lease liabilities, long-term in the consolidated balance sheet.

 

Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statements of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.

 

 18 

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Research and Development

 

Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.

 

Selling, General and Administrative

 

Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relations and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.

 

Stock Based Compensation

 

The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expenses related to share-based awards is recognized over the requisite service period, which is generally the vesting period.

 

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

Convertible Notes Payable and Derivative Instruments

 

The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. The Company also accounts for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815. Accordingly, the Company records, as a discount to convertible notes, the amount bifurcated from the convertible notes attributed to any derivatives. Debt discounts under these arrangements are amortized over the term of the related debt.

 

Series B Convertible Preferred Stock

 

The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to consolidated statement of operation in accordance with ASC 480 and ASC 815.

 

Preferred Share Redemption and Conversions

 

The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For Series A preferred stock redemptions, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. For Series B preferred stock conversions, no gain or loss is recognized upon Series B preferred stock conversion except for the fair value adjustment for the conversion and redemption feature derivative liabilities on the conversion date.

 

 19 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company adopted this guidance on April 1, 2023 and it did not have a significant impact on the Company’s consolidated financial statements.

 

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

  

As of

December 31,
2023

  

As of

March 31,
2023

 
   $   $ 
Trade and other payables   4,656,265    3,435,123 
Accrued liabilities   2,891,440    1,607,353 
Deferred revenue   11,040     
Total   7,558,745    5,042,476 

 

Trade and other payables and accrued liabilities as at December 31, 2023 and March 31, 2023 included $725,649 and $446,771, respectively, due to a shareholder, who is a director and executive of the Company.

 

5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS

 

Series A Convertible Promissory Notes:

 

During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the “Series A Notes”) sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum.

 

For the first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Company’s intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Outstanding Balance”) could be converted into that number of shares of Common Stock equal to: (i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price).

 

For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.

 

 20 

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

For the second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date.

 

For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.

 

The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing.

 

The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.

 

The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share.

 

Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features.

 

For the Series A Notes, The Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $8,088,003 and accreted the interest over the remaining lives of those Notes. The debt issuance costs were fully amortized by March 31, 2022.

 

On December 30, 2022, the Company exchanged $500,000 of Series A Notes along with its outstanding interest accrual of $121,500 into a new convertible note with the same note holder. The new convertible note has principal of $621,500, stated interest rate of 12% per annum, as well as option to convert outstanding principal and accrued interest at the conversion price, calculated at 75% multiplied by the average of the three lowest closing prices during the previous ten trading days prior to the receipt of the conversion notice. The new convertible note matured on December 30, 2023.

 

During the three and nine months ended December 31, 2023, the Company recognized discount amortization of $17,102 and $49,393, respectively, as accretion and amortization expense. As of December 31, 2023, the discount on Series A convertible notes was fully amortized. During three and nine months ended December 31, 2022, the Company recognized Nil discount amortization as the relevant discounts were fully amortized.

 

As of December 31, 2023, the Company recorded $149,184 of interest accruals for the Series A Notes.

 

 21 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Series B Convertible Notes

 

During the year ended March 31, 2021, the Company also issued $1,312,500 (face value) of convertible promissory notes (“Series B Notes”) to various accredited investors.

 

Commencing six months following the issuance date, and at any time thereafter, subject to the Company’s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “outstanding balance”) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice.

 

The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is $6.36 per share for 100,000 warrant shares and $9.0 per share for 35,417 warrant shares.

 

Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features.

 

The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount in the amount of $1,312,500 and accreted the interest over the remaining lives of those notes. The debt issuance costs were fully amortized by March 31, 2022.

 

As of December 31, 2023, the Company recorded accrued interest in the amount of $88,263 related to the Series B Notes.

 

During the three and nine months ended December 31, 2023, the Company redeemed $16,667 and $119,043 of Series B Notes, through a cash payment of $20,000 and $142,851, respectively. A gain on redemption of $2,149 and $15,281 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($5,482 and $39,089 for the three and nine months ended December 31, 2023, respectively).

 

In total, as at December 31, 2023, the Company had $200,000 and $38,677 for Series A Notes and Series B Notes remaining outstanding beyond their contractual maturity date. These continued to accrue interest, and no repayment demand notification was received from noteholders, notwithstanding the fact that these noteholders have continued to convert portions of these notes subsequently; and it is management’s expectation that all of these notes will eventually convert. In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

 

 22 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Series C Convertible Notes

 

During the three months ended June 30, 2023, the Company issued $1,017,700 (face value) in convertible promissory notes (the “Series C Notes”), in addition to $590,000 (face value) of such convertible promissory notes issued during the three months ended March 31, 2023

 

During the three months ended September 30, 2023, the Company issued additional Series C Notes in the amount of $205,000 (face value), which are convertible promissory notes sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15% per annum.

 

In total, $1,812,700 (face value) of Series C Notes were issued up to December 31, 2023.

 

The Series C Notes were sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15% per annum.

 

For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Conversion Amount”) could be converted into that number of shares of Common Stock equal to: the Conversion Amount divided by the “Optional Conversion Price”, which is defined as lower of (i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.

 

For Series C Notes, “Mandatory Conversion” of the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty (20) consecutive Trading Days (the “Measurement Period”) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.

 

The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time of final closing.

 

The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes.

 

The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing.

 

Net proceeds to the Company from Series C Notes issuance during the nine months ended December 31, 2023 amounted to $1,100,430 after payment of the relevant financing related fees.

 

 23 

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Prior to the final closing date (October 23, 2023), the Company determined that the conversion features contained in those Note, as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. Subsequently, the exercise price of all warrants was concluded and locked to $4.18 and $2.09, respectively, for the note holder and placement agent warrants, as of the final closing date October 23, 2023. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of October 23, 2023 and then transferred to equity (collectively, “End of warrants derivative treatment”).

 

For the Series C Notes, the Company recognized debt issuance costs of $Nil and $207,361 during the three and nine months ended December 31, 2023 and treated these as debt discounts. The Company also recognized additional debt discount in the amount of $Nil and $1,005,829 in connection with the recognition of derivative liabilities for the conversion features, investor warrants and placement agent warrants. The debt discounts are recorded as a contra liability against the convertible note and are amortized and recognized as accretion expenses using the effective interest method over the remaining lives of the Notes. Since total debt discount amount cannot exceed total gross proceeds upon issuance, the Company recognized accretion expenses up front of $Nil and $134,013 during the three and nine months ended December 31, 2023.

 

During the three and nine months ended December 31, 2023, the Company recognized discount amortization of $139,568 and $320,434, respectively, on Series C Notes as accretion and amortization expense. As of December 31, 2023, the remaining unamortized discount on Series C convertible notes was $ 1,471,345.

 

As of December 31, 2023, the Company recorded accrued interest in the amount of $184,911 related to the Series C Notes.

 

Convertible Preferred Notes

 

The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (“Preferred Note”) for a principal amount of $1.0 million. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly.

 

The Company also entered into a convertible preferred note financing on October 25, 2023 and issued a convertible note (“Preferred Note”) for a principal amount of $250,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly.

 

The conversion of the Preferred Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Other Convertible Notes.

 

The Company may prepay the Preferred Note in whole or in part, after providing fifteen (15) days written notice to the holder, either in cash or by the mutually consented conversion of the Preferred Note and any accrued interest thereon at a 15% discount to the stock’s 10-day VWAP.

 

As of December 31, 2023, the Company recorded accrued interest in the amount of $36,460 related to the Preferred Notes.

 

Other Convertible Preferred Notes

 

On January 23, 2023, the Company issued $2,000,000 (face value) in convertible preferred notes (“the Notes”) to an accredited investor. The Notes mature 18 months from the issuance date. This note bears interest rate at a fixed rate of 10% in the form of stock with a striker price equal to the closing stock price on the note issuance date. Therefore, the Company issued 45,045 units of common stock in lieu of interest on this convertible note. These stocks were valued at $221,621 and was recognized as a deferred cost on the convertible note, recorded as a contra liability against the convertible note, and was amortized and recognized as accretion expense using the effective interest rate method over the remaining lives of the Notes.

 

The conversion of the Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Notes.

 

During the three and nine months ended December 31, 2023, the Company recognized discount amortization of $55,861 and $166,975, respectively, for the Notes, as part of the accretion and amortization expenses. As of December 31, 2023, the remaining unamortized discount on Notes was $19,428.

 

Other Short-Term Loans, Promissory Notes and Financing Facilities 

 

In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $9,999. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 40 weeks. The Company is required to make weekly payments of $13,995 ($560,000 in the aggregate). As of December 31, 2023, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and nine months ended December 31, 2023 was nil and $6,142, respectively, and was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $Nil and $66,213 accretion expenses, during the three and nine months ended December 31, 2023, related to the increase in present value of the loan over its term.

 

In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $800,000, prior to the deduction of issuance costs in the amount of $32,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of this second agreement is 40 weeks. The Company is required to make weekly payments of $29,556 ($13,999 for the first four weeks, and $1,120,000 in the aggregate). As of December 31, 2023, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and nine months ended December 31, 2023 was $800 and $11,200, respectively, which was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $481 and $150,760 accretion expenses, during the three and nine months ended December 31, 2023, related to the increase in present value of the loan over its term.

 

 24 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $600,000 (the “Principal Amount”). The note has a fixed rate of interest at 25% per annum payable monthly on the first day of every month. This promissory note matured on December 15, 2023, when the Principal Amount became due. The note has various default provisions which would, if triggered, result in the acceleration of the Principal Amount plus any accrued and unpaid interest. The note also has a 3% early payment penalty provision. As of December 31, 2023, the amount of principal outstanding on the note was $600,000, and accrued interest outstanding on the note was $12,825. The note continues to accrue interest, and no repayment demand notification was received from noteholder.

 

On December 30, 2022, the Company extinguished 51,101 warrants that were originally issued to Series A Convertible Noteholders and replaced these warrants with a new promissory note issued to the same warrant holder. The new promissory note has principal balance of $270,000, stated interest of zero, and maturity date of December 31, 2023. The fair value of this new promissory note was $248,479 as of the issuance date, which was calculated using a discount rate that was comparable to other loan issuance at the same time as well as the market bond rates at the time of the promissory note issuance. The difference between the fair value of the new note and its principal balance was $21,521, and was recognized as a discount, and amortized via effective interest rate method. The Company compared the fair value of the extinguished warrants immediately prior to extinguishment against the fair value of the new promissory note issued. As of December 31, 2023, the obligation to repay the principal balance was waived and amount of principal outstanding on the note was $270,000, and the remaining unamortized discount was $Nil. During the three and nine months ended December 31, 2023, the Company recognized $Nil and $7,304, respectively, amortization of discount on this promissory note as accretion and amortization expenses.

 

On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $300,000, prior to the deduction of issuance costs in the amount of $12,000. The issuance costs were recognized as a debt discount and would be amortized via the effective interest method. The term of this agreement is 40 weeks. The Company is required to make weekly payments of $5,250 for the first four weeks, and $11,083 for the remaining 36 weeks, which is $420,000 in aggregate. On July 18, 2023, the Company entered into an amendment with the finance company and increased total proceeds borrowed to $700,000. The proceeds from the amended loan balance were netted against previously outstanding balance of the loan, along with an issuance cost in the amount of $28,000. The term of this new loan agreement is 40 weeks. The Company is required to make weekly payments of $24,500, which is $980,000 in aggregate. The Company accounted for this amendment as a debt extinguishment and recognized a loss on the amendment of $59,161 in other expenses. The issuance costs on the amended loan were recognized as a debt discount and would be amortized via the effective interest method. As of December 31, 2023, the amount of principal outstanding under this amended agreement was $357,445 and the remaining unamortized issuance cost discount was $11,900. During the three and nine months ended December 31, 2023, the Company recognized $9,100 and $16,100, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $108,245 and $300,651 accretion expenses, during the three and nine months ended December 31, 2023, related to the increase in present value of the loan over its term.

 

In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the “Revolving Facility”) with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities. The inventory financing provided by this facility was limited to the lower of $0.3 million, or a 40% maximum of inventory balances. The Revolving Facility was accounted for as a secured borrowing. As of December 31, 2023, the Company had drawn $891,111 in accounts receivable financing and $300,000 in inventory financing with aggregate principal outstanding of $1,191,111.

 

On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $400,000, prior to the deduction of issuance costs in the amount of $24,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 14 weeks. The Company is required to make weekly payments of $38,705 ($540,000 in the aggregate). As of December 31, 2023, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the three and nine months ended December 31, 2023 was $5,143 and $24,000 respectively and was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $10,949 and $141,870 accretion expenses during the three and nine months ended December 31, 2023, related to the increase in present value of the loan over its term.

 

On August 11, 2023, the Company issued two short term promissory notes (“August 2023 Notes”), each for a principal amount of $250,000, to one investor for aggregate gross proceeds of $500,000. The August 2023 Notes do not accrue formal interest, but do contain administrative fees in the aggregate of $75,000. One of the notes matures three months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $25,000 is due. The second note matures six months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $50,000 is due. The administrative fees were accrued as interest expenses for the period of the loans outstanding. As of December 31, 2023, the amount of principal outstanding on the note was $500,000, and accrued interest outstanding on the note was $62,500.

 

On December 8, 2023, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $630,000, prior to the deduction of issuance costs in the amount of $15,750. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is 44 weeks. The Company is required to make weekly payments of $19,195 ($844,200 in the aggregate). As of December 31, 2023, the amount of principal outstanding under this amended agreement was $598,014 and the remaining unamortized issuance cost discount was $14,676. During the three and nine months ended December 31, 2023, the Company recognized $1,074 and $1,074, respectively, of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $25,599 and $25,599 accretion expenses during the three and nine months ended December 31, 2023, related to the increase in present value of the loan over its term.

 

 25 

 

 

BIOTRICITY INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

Total interest expense on the above convertible notes, short-term loan and promissory notes was $284,898 and $69,930 for the three months ended December 31, 2023 and 2022, respectively, and $689,493 and $126,574 during the nine months ended December 31, 2023 and 2022, respectively.

 

Total accretion expenses on the above convertible notes, short-term loan and promissory notes were $370,755 and Nil for the three months ended December 31, 2023 and 2022, respectively, and $1,421,729 and Nil during the nine months ended December 31, 2023 and 2022, respectively.

 

6. TERM LOAN AND CREDIT AGREEMENT

 

Term Loan

 

On December 21, 2021, the Company entered into a Credit Agreement (“Credit Agreement”) with SWK Funding LLC (“Lender’); as part of this, the Company has borrowed $12.4 million, with a maturity date of December 21, 2026. The principal will accrue interest at the LIBOR Rate plus 10.5% per annum (subject to adjustment as set forth in the Credit Agreement). Interest payments are due each February, May, August and November commencing February 15, 2022. Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances. Pursuant to the Credit Agreement the Company is subject to an Origination Fee in the amount of $120,000. Upon Termination of the Credit Agreement, the Company shall pay an Exit Fee of $600,000. 

 

As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $50,000 in cash.

 

Total costs directly in connection to the debt financing in the amount of $193,437 (professional fee $48,484; lender’s origination fee, due diligence fee, and other expenses in the amount of $144,953) was deduced from the gross proceeds in the amount of $12,000,000.

 

The Company also repaid $1,574,068 of existing short-term loan and promissory notes and relevant accrued interests by using the proceeds from the loan.

 

Total costs directly in connection to the loan and fair value of warrants were in the amount of $1,042,149, and such costs were accounted as debt discount and amortized using the effective interest method. The amortization of such debt discount was included in the accretion and amortization expenses. For the three months ended December 31, 2023 and 2022, the amortization of debt discount expense was $51,950 and $51,061, respectively, and $154,616 and $151,971 during the nine months ended December 31, 2023 and 2022, respectively.

 

Total interest expense on the term loan for the three months ended December 31, 2023 and 2022 was $496,952 and $389,662, respectively, and $1,489,764 and $1,054,166 during the nine months ended December 31, 2023 and 2022, respectively. During November 2022, the unpaid interest of $364,000 was added to the outstanding principal balance, since then interest onwards would be calculated on the updated principal balance.

 

The Company had accrued interest payable of $455,620 and $239,614, respectively, as of December 31, 2023 and March 31, 2023.

 

The Company and Lender also entered into a Guarantee and Collateral Agreement (“Collateral Agreement”) wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the “IP Security Agreement”) wherein the Credit Agreement is also secured by the Company’s right title and interest in the Company’s Intellectual Property.

 

 26 

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

In connection with the Credit Agreement, the Company issued 9,590 warrants (as adjusted for the Reverse Split) to the Lender, which were fair-valued at $198,713 at issuance (Note 9). The warrants are accounted as a deduction from liability as well as a credit into additional paid-in capital, and amortized using the effective interest method.

 

At December 31, 2023, the Company was not in compliance with certain covenants of the term loan, for which it sought and received relief from the term loan lender.

 

7. FEDERALLY GUARANTEED LOAN

 

Economic Injury Disaster Loan (“EIDL”)

 

In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in the first 12 months. The Company may prepay the loan without penalty at will.

 

In May 2021, the Company received an additional $499,900 from the SBA under the same terms.

 

As of December 31, 2023, the Company recorded accrued interest of $35,846 for the EIDL loan (March 31, 2023: $65,247).

 

Interest expense on the above loan was $8,231 and $8,230 for the three months ended December 31, 2023 and 2022, respectively, and $24,603 and $24,602 for the nine months ended December 31, 2023 and 2022, respectively.

 

8. DERIVATIVE LIABILITIES

 

The Company analyzed the compound features of variable conversion and redemption embedded in the series A and series B preferred shares instruments, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the nine months ended December 31, 2023 and 2022:

   2023   2022 
   $   $ 
Derivative liabilities, beginning of period   759,065    352,402 
Derivative liabilities recognized pursuant to issuance of Series B preferred shares (Note 9)   642,417     
Change in fair value of derivatives during period   (142,830)   442,309 
Reduction due to preferred shares converted   (119,359)   (53,036)
Derivative liabilities, end of period   1,139,293    741,675 

 

The lattice methodology was used to value the derivative components, using the following assumptions during the nine months ended December 31, 2023 and 2022:

   2023   2022 
Dividend yield (%)   12    12 
Risk-free rate for term (%)   4.713.7    2.14.4 
Volatility (%)   71.9119.1    85.4102 
Remaining terms (Years)   0.252.01    1 3.01 
Stock price ($ per share)   0.643.82    0.4510.62 

 

 27 

 

 

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2023 (Unaudited)

(Expressed in US dollars)

 

In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. A roll-forward of activity is presented below for the nine months ended December 31, 2023 and 2022:

   2023   2022 
   $   $ 
         
Balance beginning of period – March 31   1,008,216    520,747 
New Issuance   1,224,933     
Conversion to common shares   (39,089)   (192,794)
Change in fair value of derivative liabilities   386,845    27,662 
End of derivative treatment   (1,652,572)   (17,979)
Convertible note modification       (53,402)
Balance end of period – December 31   928,333    351,719 

 

The Monte-Carlo methodology was used to value the convertible note and warrant derivative components during the six months ended December 31, 2023 and 2022, using the following assumptions:

    2023    2022 
Risk-free rate for term (%)   4.25.3     4.44.4  
Volatility (%)   76.2126.6     94102  
Remaining terms (Years)   0.251.49     11  
Stock price ($ per share)   0.463.04     0.450.45  

 

9. STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY

 

(a) Authorized and Issued Stock

 

As at December 31, 2023, the Company is authorized to issue 125,000,000 (March 31, 2023 – 125,000,000) shares of common stock ($0.001 par value), and 10,000,000 (March 31, 2023 – 10,000,000) shares of preferred stock ($0.001 par value), of which 20,000 (March 31, 2023 – 20,000) are designated shares of Series A preferred stock ($0.001 par value) and 600 (March 31, 2023 – nil) are designated shares of Series B preferred stock ($0.001 par value).

 

At December 31, 2023, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding totaled 9,419,629 (March 31, 2023 – 8,752,505) shares; these were comprised of 9,258,957 (March 31, 2023 – 8,508,052) shares of common stock and 160,672 (March 31, 2023 – 244,458) exchangeable shares. At December 31, 2023, there were 6,304 shares of Series A Preferred Stock that were issued and outstanding (March 31, 2023 –